SEARCH

SEARCH BY CITATION

References

  • 1
    Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
  • 2
    Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 221-230.
  • 3
    Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718-724.
  • 4
    Powell LW, Dixon JL, Ramm GA, Purdie DM, Lincoln DJ, Anderson GJ, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006; 166: 294-301.
  • 5
    Adams PC, Passmore L, Chakrabarti S, Reboussin DM, Acton RT, Barton JC, et al. Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 2006; 4: 918-923.
  • 6
    Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003; 124: 318-326.
  • 7
    Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DHG. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002; 122: 281-289.
  • 8
    Adams PC, Agnew S. Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings. HEPATOLOGY 1996; 23: 724-727.
  • 9
    Scotet V, Merour M-C, Mercier A-Y, Chanu B, Le Faou T, Raguenes O, et al. Hereditary hemochromatosis: effect of excessive alcohol consumption on disease expression in patients homozygous for the C282Y mutation. Am J Epidemiol 2003; 158: 129-134.
  • 10
    Powell EE, Ali A, Clouston AD, Dixon JL, Lincoln DJ, Purdie DM, et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 2005; 129: 1937-1943.
  • 11
    Adams LA, Angulo P, Abraham SC, Torgerson H, Brandhagen D. The effect of the metabolic syndrome, hepatic steatosis, and steatohepatitis on liver fibrosis in hereditary hemochromatosis. Liver Int 2006; 26: 298-304.
  • 12
    Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet 2011; 377: 557-567.
  • 13
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
  • 14
    Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the Metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
  • 15
    Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-728.
  • 16
    Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. HEPATOLOGY 1999; 30: 1356-1362.
  • 17
    Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1224-1229.
  • 18
    Lo L, McLennan SV, Williams PF, Bonner J, Chowdhury S, McCaughan GW, et al. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J Hepatol 2011; 55: 435-444.
  • 19
    Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. HEPATOLOGY 2002; 36: 729-736.
  • 20
    Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002; 97: 2408-2414.
    Direct Link:
  • 21
    Kita Y, Mizukoshi E, Takamura T, Sakurai M, Takata Y, Arai K, et al. Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus. Metabolism 2007; 56: 1682-1688.
  • 22
    Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology 2003; 125: 1695-1704.
  • 23
    Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; 35: 279-283.
  • 24
    Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput J. Excess weight risk factor for alcoholic liver disease. HEPATOLOGY 1997; 25: 108-111.
  • 25
    Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput J-C, Naveau S. Risk factors of fibrosis in alcohol-induced liver disease. HEPATOLOGY 2002; 35: 635-638.
  • 26
    Lee IC, Huang YH, Chan CC, Huo T, Chu CJ, Lai CR, et al. Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. Clin Nutr 2011; 30: 647-652.
  • 27
    Wong GLH, Wong VWS, Choi PCL, Chan AWH, Chim AML, Yiu KKL, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009; 58: 111-117.
  • 28
    Strohmeyer G, Niederau C, Stremmel W. Survival and causes of death in hemochromatosis. Observations in 163 patients. Ann N Y Acad Sci 1988; 526: 245-257.
  • 29
    Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—the Evidence Report. National Institutes of Health. Obes Res 1998; 6 51S-209S.
  • 30
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-2571.
  • 31
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143.
  • 32
    American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care 2011; 34(Suppl 1): S11-S61.
  • 33
    Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol 1973; 26: 770-772.
  • 34
    Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374.
  • 35
    Searle JW, Kerr JF, Halliday JW, Powell LW. Iron storage disease. In: MacSween RM, Anthony PP, Scheuer PJ, eds. Pathology of the Liver, 2nd ed. Edinburgh, Scotland: Churchill Livingstone; 1987: 257-272.
  • 36
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
    Direct Link:
  • 37
    Wood MJ, Powell LW, Ramm GA. Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 2008; 111: 4456-4462.
  • 38
    Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107-1119.
  • 39
    Stocks AE, Powell LW. Carbohydrate intolerance in idiopathic haemochromatosis and cirrhosis of the liver. QJM 1973; 42: 733-749.
  • 40
    Fracanzani AL, Piperno A, Valenti L, Fraquelli M, Coletti S, Maraschi A, et al. Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors. HEPATOLOGY 2010; 51: 501-510.
  • 41
    Walsh A, Dixon JL, Ramm GA, Hewett DG, Lincoln DJ, Anderson GJ, et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 2006; 4: 1403-1410.
  • 42
    Dey A, Swaminathan K. Hyperglycemia-induced mitochondrial alterations in liver. Life Sci 2010; 87: 197-214.
  • 43
    Ramm GA, Ruddell RG. Iron homeostasis, hepatocellular injury, and fibrogenesis in hemochromatosis: the role of inflammation in a noninflammatory liver disease. Semin Liver Dis 2010; 30: 271-287.
  • 44
    Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, Bhathal PS, et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007; 133: 80-90.
  • 45
    McClain D, Abraham D, Rogers J, Brady R, Gault P, Ajioka R, Kushner J. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia 2006; 49: 1661-1669.
  • 46
    Hramiak IM, Finegood DT, Adams PC. Factors affecting glucose tolerance in hereditary hemochromatosis. Clin Invest Med 1997; 20: 110-118.
  • 47
    Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011; 55: 920-932.
  • 48
    Dongiovanni P, Valenti L, Rametta R, Daly AK, Nobili V, Mozzi E, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 267-273.
  • 49
    Altamirano J, Bataller R. Cigarette smoking and chronic liver diseases. Gut 2010; 59: 1159-1162.
  • 50
    Zein CO, Unalp A, Colvin R, Liu Y-C, McCullough AJ. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol 2011; 54: 753-759.